Nurix Therapeutics Inc (NRIX) concluded trading on Thursday at a closing price of $12.67, with 4.41 million shares of worth about $55.9 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -34.08% during that period and on July 10, 2025 the price saw a loss of about -3.87%. Currently the company’s common shares owned by public are about 76.43M shares, out of which, 74.71M shares are available for trading.
Stock saw a price change of 1.85% in past 5 days and over the past one month there was a price change of 1.04%. Year-to-date (YTD), NRIX shares are showing a performance of -38.20% which decreased to -32.75% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $8.18 but also hit the highest price of $29.56 during that period. The average intraday trading volume for Nurix Therapeutics Inc shares is 904.64K. The stock is currently trading 5.29% above its 20-day simple moving average (SMA20), while that difference is up 12.96% for SMA50 and it goes to -25.34% lower than SMA200.
Nurix Therapeutics Inc (NASDAQ: NRIX) currently have 76.43M outstanding shares and institutions hold larger chunk of about 110.66% of that.
The stock has a current market capitalization of $968.61M and its 3Y-monthly beta is at 2.15. It has posted earnings per share of -$2.61 in the same period. It has Quick Ratio of 6.82 while making debt-to-equity ratio of 0.12. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NRIX, volatility over the week remained 8.61% while standing at 6.42% over the month.
Stock’s fiscal year EPS is expected to drop by -0.43% while it is estimated to decrease by -19.64% in next year. EPS is likely to grow at an annualized rate of -4.90% for next 5-years, compared to annual growth of -38.86% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Leerink Partners on March 17, 2025 offering a Market perform rating for the stock and assigned a target price of $16 to it. Coverage by BTIG Research stated Nurix Therapeutics Inc (NRIX) stock as a Buy in their note to investors on December 10, 2024, suggesting a price target of $35 for the stock. On December 06, 2024, BMO Capital Markets Initiated their recommendations, while on October 24, 2024, UBS Initiated their ratings for the stock with a price target of $35. Stock get a Buy rating from Jefferies on October 11, 2024.
